Plain-English translation of NCT06931080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called EB-1020 to see if it can help adults with ADHD (attention-deficit/hyperactivity disorder) manage their symptoms. Researchers want to find out if this once-daily capsule is safe and effective at two different doses. The medication is being compared to a placebo—a dummy pill with no active ingredient—to make sure any improvements are real.
Many adults with ADHD struggle to find treatments that work well for them or that fit into their daily routine. This trial is exploring whether this new medication could offer a better option for managing focus, attention, and impulse control.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit a research clinic multiple times for medical evaluations and blood tests. You will take either the new medication at one of two doses or a placebo capsule once daily by mouth. The study compares three groups to see which dose—if any—works best, and researchers will monitor you closely for safety and how well the treatment is working.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
Japan
Phase
Large-scale testing
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Enrollment target
~630 participants
Started
April 2025
Primary completion
December 2027
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in August 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.